Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

NICE to say no to Tarceva

November 17, 2006 Sales and Marketing NICE, Tarceva

Roche's new lung cancer treatment Tarceva looks set to be refused recommendation from NICE.Tarceva (erlotinib) is the first next-generation treatment …
News

Surprise delay for Novartis’ Galvus

November 15, 2006 Sales and Marketing Galvus, diabetes

The FDA will take three months longer than expected to review Novartis' new diabetes treatment, Galvus, after the pharma company …
News

Trained to win

November 13, 2006 Business Services, Sales and Marketing marketing, sales, training

Pharmaceutical sales and marketing managers have a dizzying array of training courses, educational aids and events at their disposal, all …
Feature

Genentech to buy biotech Tanox for $900 million

November 10, 2006 Sales and Marketing Genentech

 Genentech is to pay $919 million for Tanox, a biotech company which specialises in monoclonal antibodies.Genentech has been working with …
News

iPod-ready patient information leaflets coming soon

November 10, 2006 Sales and Marketing patients

From next month, patients will be able to learn about their medicines by listening to an iPod, MP3 player or …
News

US Democrats to target pharmaceutical prices

November 10, 2006 Sales and Marketing

 The decisive victory of the Democrat party in the US mid-term elections looks set to bring new pressure on pharmaceutical …
News

Abbott buys cholesterol drug specialists Kos

November 9, 2006 Sales and Marketing

Abbott is to pay $3.7 billion for Kos, the specialist US pharma company which has developed a number of major …
News

Once-a-day colitis drug could take on the leaders

November 7, 2006 Sales and Marketing

Shire is hoping its new, one-a-day treatment approach for ulcerative colitis (UC) will give the market leaders a run for …
News

First class relationships

November 6, 2006 Medical Communications, Sales and Marketing industry relations, key opinion leaders, pharma

Pharma goes 'no frillls'Provocative headlines drawing attention to inappropriate behaviour and misconduct in the medical and pharmaceutical professions have been …
Feature

New drive to cut millions from branded sales on NHS

November 3, 2006 Sales and Marketing generics

Some of the UK's top selling medicines are to be targeted in a new NHS drive to cut millions from …
News

Teva and Schering-Plough UK to collaborate on bowel drug

November 3, 2006 Sales and Marketing

Teva has signed a deal with Schering-Plough UK to co-promote its ulcerative colitis and Crohn's disease treatment, Mesren.Teva hopes that …
News

UK industry launches ‘manifesto’ to speed uptake of new medicines

November 2, 2006 Sales and Marketing

Pharmaceutical industry organisation, the ABPI, has launched a new campaign to increase the uptake of new medicines in the UK, …
News

Pharma’s evolving relationship with NICE

November 1, 2006 Research and Development, Sales and Marketing NHS, NICE, approval process, fast track, healthcare

Back when New Labour was only halfway through its first term of office and when the Millennium Bug was feared …
Feature

Bristol-Myers Squibb suffers at hands of generic Plavix

October 26, 2006 Sales and Marketing

Figures show that the launch of a generic competitor to Plavix in the US dealt a serious blow to Bristol-Myers …
News

Takeda launches Actos combination in UK

October 26, 2006 Sales and Marketing

 Takeda has expanded its type II diabetes portfolio in the UK with the launch of Competact, a combination of the …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026